Nasus Pharma Ltd Logo

Nasus Pharma Ltd

Develops powder-based intranasal drugs for rapid delivery in acute medical emergencies.

NSRX | US

Overview

Corporate Details

ISIN(s):
N/A
LEI:
Country:
United States of America
Address:
29 HARAKEVET ST, 6618003 TEL AVIV - YAFO
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Nasus Pharma Ltd. is a clinical-stage pharmaceutical company specializing in the development of powder-based intranasal (PBI) products for acute medical conditions and emergency situations. Leveraging its proprietary microsphere technology, the company aims to provide rapid, non-invasive drug delivery to the bloodstream and brain, bypassing the blood-brain barrier. This technology is designed for superior absorption compared to traditional liquid-based solutions. Nasus Pharma's product portfolio targets public health threats and emergency medical needs, including treatments for severe allergic reactions and opioid overdose.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Nasus Pharma Ltd filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Nasus Pharma Ltd

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Nasus Pharma Ltd via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

SOLIGENIX, INC. Logo
Late-stage biopharma developing treatments for rare diseases and public health threats.
United States of America
SNGX
Sonnet BioTherapeutics Holdings, Inc. Logo
Develops targeted cytokine therapies for cancer using a proprietary albumin-binding platform.
United States of America
SONN
Sonoma Pharmaceuticals, Inc. Logo
Develops and sells stabilized HOCl products for wound, skin, eye, nasal, and animal healthcare.
United States of America
SNOA
Sopharma AD Logo
Develops, manufactures, and distributes pharmaceuticals and generics in Bulgaria and regional markets.
Bulgaria
SFA
Spago Nanomedical AB Logo
Developing nanomedicines for precise cancer diagnosis and targeted radionuclide therapy.
Sweden
SPAGO
Spero Therapeutics, Inc. Logo
Develops novel treatments for multi-drug resistant bacterial infections and rare diseases.
United States of America
SPRO
Spexis AG Logo
Clinical-stage biopharma developing macrocyclic therapeutics for rare diseases and oncology.
Switzerland
SPEX
Sprint Bioscience Logo
Develops & out-licenses preclinical oncology drugs for difficult-to-treat cancers.
Sweden
SPRINT
SPRUCE BIOSCIENCES, INC. Logo
Developing first-in-class therapies for serious, underserved neurological conditions like MPS IIIB.
United States of America
SPRB
Spyre Therapeutics, Inc. Logo
Engineering advanced antibody therapies for IBD and other immune diseases.
United States of America
SYRE

Talk to a Data Expert

Have a question? We'll get back to you promptly.